PortalPublikationenHaploidentical transplant in patients with myelodysplastic s...

Haploidentical transplant in patients with myelodysplastic syndrome

Standard

Haploidentical transplant in patients with myelodysplastic syndrome. / Robin, Marie; Porcher, Raphael; Ciceri, Fabio; van Lint, Maria Teresa; Santarone, Stella; Ehninger, Gerhard; Blaise, Didier; Güllbas, Zafer; Gonzáles Muñiz, Soledad; Michallet, Mauricette; Velardi, Andrea; Koster, Linda; Maertens, Johan; Sierra, Jorge; Selleslag, Dominik; Radujkovic, Aleksandar; Díez-Martin, José L; Kanz, Lothar; Arroyo, Concepcion Herrera; Niederwieser, Dietger; Huang, He; McDonald, Andrew; de Witte, Theo; Koc, Yener; Kröger, Nicolaus.

in: BLOOD ADV, Jahrgang 1, Nr. 22, 10.10.2017, S. 1876-1883.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Robin, M, Porcher, R, Ciceri, F, van Lint, MT, Santarone, S, Ehninger, G, Blaise, D, Güllbas, Z, Gonzáles Muñiz, S, Michallet, M, Velardi, A, Koster, L, Maertens, J, Sierra, J, Selleslag, D, Radujkovic, A, Díez-Martin, JL, Kanz, L, Arroyo, CH, Niederwieser, D, Huang, H, McDonald, A, de Witte, T, Koc, Y & Kröger, N 2017, 'Haploidentical transplant in patients with myelodysplastic syndrome', BLOOD ADV, Jg. 1, Nr. 22, S. 1876-1883. https://doi.org/10.1182/bloodadvances.2017007146

APA

Robin, M., Porcher, R., Ciceri, F., van Lint, M. T., Santarone, S., Ehninger, G., Blaise, D., Güllbas, Z., Gonzáles Muñiz, S., Michallet, M., Velardi, A., Koster, L., Maertens, J., Sierra, J., Selleslag, D., Radujkovic, A., Díez-Martin, J. L., Kanz, L., Arroyo, C. H., ... Kröger, N. (2017). Haploidentical transplant in patients with myelodysplastic syndrome. BLOOD ADV, 1(22), 1876-1883. https://doi.org/10.1182/bloodadvances.2017007146

Vancouver

Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G et al. Haploidentical transplant in patients with myelodysplastic syndrome. BLOOD ADV. 2017 Okt 10;1(22):1876-1883. https://doi.org/10.1182/bloodadvances.2017007146

Bibtex

@article{99aee0c9dc884c2ca663dc0cb0270962,
title = "Haploidentical transplant in patients with myelodysplastic syndrome",
abstract = "The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option. The present study reports the European Group for Blood and Marrow Transplantation activity for haploidentical transplantation in MDS patients. A total of 228 patients transplanted from a mismatched HLA-related donor between 2007 and 2014 were studied. The median age at transplant was 56 years. Eighty-four (37%) patients had MDS transformed into acute myeloid leukemia at the time of transplant. Ex vivo T-cell depletion was used in 34 patients. One hundred ninety-four patients received a T-cell replete transplant and 102 patients received posttransplant cyclophosphamide (PT-CY) as graft-versus-host disease (GVHD) prophylaxis. The cumulative incidences of acute and chronic GVHD in PT-CY vs other patients were 25% vs 37% and 37% vs 24%, respectively. The cumulative incidence of nonrelapse mortality was 55% in patients who did not receive PT-CY (no PT-CY) and 41% in patients who did receive PT-CY. Three-year overall survival was 28% in no PT-CY patients and 38% in PT-CY patients. In multivariable analysis, the main risk factors were the intensity of the conditioning regimen and the use of PT-CY. In conclusion, the outcomes of MDS patients who received an haploidentical transplant are close to the results other transplantations from HLA-mismatched donors with approximately one-third of patients alive and free of disease 3 years after transplant, and the use of PT-CY may improve their outcomes.",
keywords = "Journal Article",
author = "Marie Robin and Raphael Porcher and Fabio Ciceri and {van Lint}, {Maria Teresa} and Stella Santarone and Gerhard Ehninger and Didier Blaise and Zafer G{\"u}llbas and {Gonz{\'a}les Mu{\~n}iz}, Soledad and Mauricette Michallet and Andrea Velardi and Linda Koster and Johan Maertens and Jorge Sierra and Dominik Selleslag and Aleksandar Radujkovic and D{\'i}ez-Martin, {Jos{\'e} L} and Lothar Kanz and Arroyo, {Concepcion Herrera} and Dietger Niederwieser and He Huang and Andrew McDonald and {de Witte}, Theo and Yener Koc and Nicolaus Kr{\"o}ger",
year = "2017",
month = oct,
day = "10",
doi = "10.1182/bloodadvances.2017007146",
language = "English",
volume = "1",
pages = "1876--1883",
journal = "BLOOD ADV",
issn = "2473-9529",
publisher = "Elsevier BV",
number = "22",

}

RIS

TY - JOUR

T1 - Haploidentical transplant in patients with myelodysplastic syndrome

AU - Robin, Marie

AU - Porcher, Raphael

AU - Ciceri, Fabio

AU - van Lint, Maria Teresa

AU - Santarone, Stella

AU - Ehninger, Gerhard

AU - Blaise, Didier

AU - Güllbas, Zafer

AU - Gonzáles Muñiz, Soledad

AU - Michallet, Mauricette

AU - Velardi, Andrea

AU - Koster, Linda

AU - Maertens, Johan

AU - Sierra, Jorge

AU - Selleslag, Dominik

AU - Radujkovic, Aleksandar

AU - Díez-Martin, José L

AU - Kanz, Lothar

AU - Arroyo, Concepcion Herrera

AU - Niederwieser, Dietger

AU - Huang, He

AU - McDonald, Andrew

AU - de Witte, Theo

AU - Koc, Yener

AU - Kröger, Nicolaus

PY - 2017/10/10

Y1 - 2017/10/10

N2 - The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option. The present study reports the European Group for Blood and Marrow Transplantation activity for haploidentical transplantation in MDS patients. A total of 228 patients transplanted from a mismatched HLA-related donor between 2007 and 2014 were studied. The median age at transplant was 56 years. Eighty-four (37%) patients had MDS transformed into acute myeloid leukemia at the time of transplant. Ex vivo T-cell depletion was used in 34 patients. One hundred ninety-four patients received a T-cell replete transplant and 102 patients received posttransplant cyclophosphamide (PT-CY) as graft-versus-host disease (GVHD) prophylaxis. The cumulative incidences of acute and chronic GVHD in PT-CY vs other patients were 25% vs 37% and 37% vs 24%, respectively. The cumulative incidence of nonrelapse mortality was 55% in patients who did not receive PT-CY (no PT-CY) and 41% in patients who did receive PT-CY. Three-year overall survival was 28% in no PT-CY patients and 38% in PT-CY patients. In multivariable analysis, the main risk factors were the intensity of the conditioning regimen and the use of PT-CY. In conclusion, the outcomes of MDS patients who received an haploidentical transplant are close to the results other transplantations from HLA-mismatched donors with approximately one-third of patients alive and free of disease 3 years after transplant, and the use of PT-CY may improve their outcomes.

AB - The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option. The present study reports the European Group for Blood and Marrow Transplantation activity for haploidentical transplantation in MDS patients. A total of 228 patients transplanted from a mismatched HLA-related donor between 2007 and 2014 were studied. The median age at transplant was 56 years. Eighty-four (37%) patients had MDS transformed into acute myeloid leukemia at the time of transplant. Ex vivo T-cell depletion was used in 34 patients. One hundred ninety-four patients received a T-cell replete transplant and 102 patients received posttransplant cyclophosphamide (PT-CY) as graft-versus-host disease (GVHD) prophylaxis. The cumulative incidences of acute and chronic GVHD in PT-CY vs other patients were 25% vs 37% and 37% vs 24%, respectively. The cumulative incidence of nonrelapse mortality was 55% in patients who did not receive PT-CY (no PT-CY) and 41% in patients who did receive PT-CY. Three-year overall survival was 28% in no PT-CY patients and 38% in PT-CY patients. In multivariable analysis, the main risk factors were the intensity of the conditioning regimen and the use of PT-CY. In conclusion, the outcomes of MDS patients who received an haploidentical transplant are close to the results other transplantations from HLA-mismatched donors with approximately one-third of patients alive and free of disease 3 years after transplant, and the use of PT-CY may improve their outcomes.

KW - Journal Article

U2 - 10.1182/bloodadvances.2017007146

DO - 10.1182/bloodadvances.2017007146

M3 - SCORING: Journal article

C2 - 29296834

VL - 1

SP - 1876

EP - 1883

JO - BLOOD ADV

JF - BLOOD ADV

SN - 2473-9529

IS - 22

ER -